224 related articles for article (PubMed ID: 37455550)
41. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
42. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.
Zheng Q; Bai L; Zheng S; Liu M; Zhang J; Wang T; Xu Z; Chen Y; Li J; Duan Z
Mol Med Rep; 2017 Nov; 16(5):7199-7204. PubMed ID: 28944845
[TBL] [Abstract][Full Text] [Related]
43. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
[TBL] [Abstract][Full Text] [Related]
44. Gene Editing Technologies to Target HBV cccDNA.
Martinez MG; Smekalova E; Combe E; Gregoire F; Zoulim F; Testoni B
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560658
[TBL] [Abstract][Full Text] [Related]
45. Targeting Hepatitis B Virus DNA Using Designer Gene Editors.
Zhang H; Tu T
Clin Liver Dis; 2023 Nov; 27(4):895-916. PubMed ID: 37778776
[TBL] [Abstract][Full Text] [Related]
46. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
47. An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation.
Li H; Sheng C; Liu H; Liu G; Du X; Du J; Zhan L; Li P; Yang C; Qi L; Wang J; Yang X; Jia L; Xie J; Wang L; Hao R; Xu D; Tong Y; Zhou Y; Zhou J; Sun Y; Li Q; Qiu S; Song H
Int J Biol Sci; 2016; 12(9):1104-13. PubMed ID: 27570484
[TBL] [Abstract][Full Text] [Related]
48. Establishment of Cre-mediated HBV recombinant cccDNA (rcccDNA) cell line for cccDNA biology and antiviral screening assays.
Wu M; Li J; Yue L; Bai L; Li Y; Chen J; Zhang X; Yuan Z
Antiviral Res; 2018 Apr; 152():45-52. PubMed ID: 29432776
[TBL] [Abstract][Full Text] [Related]
49.
Kayesh MEH; Hashem MA; Kohara M; Tsukiyama-Kohara K
Front Microbiol; 2022; 13():953218. PubMed ID: 35847068
[TBL] [Abstract][Full Text] [Related]
50. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
51. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.
Karimova M; Beschorner N; Dammermann W; Chemnitz J; Indenbirken D; Bockmann JH; Grundhoff A; Lüth S; Buchholz F; Schulze zur Wiesch J; Hauber J
Sci Rep; 2015 Sep; 5():13734. PubMed ID: 26334116
[TBL] [Abstract][Full Text] [Related]
52. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals.
Huang H; Wang J; Li W; Chen R; Chen X; Zhang F; Xu D; Lu F
J Clin Virol; 2018; 99-100():71-78. PubMed ID: 29353073
[TBL] [Abstract][Full Text] [Related]
53. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation.
Zhang W; Chen J; Wu M; Zhang X; Zhang M; Yue L; Li Y; Liu J; Li B; Shen F; Wang Y; Bai L; Protzer U; Levrero M; Yuan Z
Hepatology; 2017 Aug; 66(2):398-415. PubMed ID: 28236308
[TBL] [Abstract][Full Text] [Related]
54. [Novel vector preS1-tp fusion protein effectively inhibits hepatitis B virus replication and cccDNA synthesis by mediating hepatitis B virus targeting sequence small interfering RNA].
Zeng YL; Gao F; Zhang C; Wei JF; Ma L; Ding GG; Li W; Shang J; Kang Y
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):126-132. PubMed ID: 33685080
[No Abstract] [Full Text] [Related]
55. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
Ko C; Chakraborty A; Chou WM; Hasreiter J; Wettengel JM; Stadler D; Bester R; Asen T; Zhang K; Wisskirchen K; McKeating JA; Ryu WS; Protzer U
J Hepatol; 2018 Dec; 69(6):1231-1241. PubMed ID: 30142426
[TBL] [Abstract][Full Text] [Related]
56. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.
Yan Z; Zeng J; Yu Y; Xiang K; Hu H; Zhou X; Gu L; Wang L; Zhao J; Young JAT; Gao L
J Hepatol; 2017 Jun; 66(6):1149-1157. PubMed ID: 28213165
[TBL] [Abstract][Full Text] [Related]
57. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
[TBL] [Abstract][Full Text] [Related]
58. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9.
Kostyushev D; Kostyusheva A; Brezgin S; Zarifyan D; Utkina A; Goptar I; Chulanov V
Sci Rep; 2019 Feb; 9(1):1847. PubMed ID: 30755668
[TBL] [Abstract][Full Text] [Related]
59. Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing.
Zhou H; Wang X; Steer CJ; Song G; Niu J
Hepatol Commun; 2022 Jul; 6(7):1652-1663. PubMed ID: 35338607
[TBL] [Abstract][Full Text] [Related]
60. Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation.
Zhong Y; Wu C; Xu Z; Teng Y; Zhao L; Zhao K; Wang J; Wang W; Zhan Q; Zhu C; Chen X; Liang K; Cheng X; Xia Y
J Virol; 2022 Nov; 96(21):e0136222. PubMed ID: 36226986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
